Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M Galvez Madroñero"'
Autor:
M Galvez Madroñero, FJ Peñalver Parraga, MI Barcia Martin, M Pérez Encinas, L Villalon Blanco, P Sanmartin Fenollera
Publikováno v:
Eur J Hosp Pharm
Background Ibrutinib is a tyrosine kinase inhibitor indicated for treatment of chronic lymphocytic leukaemia (CLL) among other pathologies. In the literature its considered a safe drug, however, one of the adverse reactions described in the data shee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eca71cbd2020449bf4d355a1e408220
https://doi.org/10.1136/ejhpharm-2018-eahpconf.423
https://doi.org/10.1136/ejhpharm-2018-eahpconf.423
Autor:
M Galvez Madroñero, M Pérez Figueras, L Moreno Nuñez, S Sanz Márquez, M Pérez Encinas, A Usarralde Pérez
Publikováno v:
Eur J Hosp Pharm
Background Piperacillin/tazobactam (PT) is a combination of broad-spectrum antibiotics. PT is frequently used as an empirical treatment in moderate and severe infections of different origin. PT is mainly used to cover polymicrobial flora with the par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a945847bde9163d9653b3e7d03acb45d
https://doi.org/10.1136/ejhpharm-2018-eahpconf.149
https://doi.org/10.1136/ejhpharm-2018-eahpconf.149
Autor:
M Galvez Madroñero, AM Martín De Rosales Cabrera, S Esteban Casado, M Pérez Encinas, A Usarralde Pérez, EA Álvaro Alonso
Publikováno v:
European Journal of Hospital Pharmacy. 23:A230.2-A230
Background There are different factors to be considered before administering a drug through a feeding tube in order to prevent medication errors, tube obstruction, reduction of drug effectiveness and an increased risk of toxicity. Purpose This articl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4008cf302aef40818fc5dc4ef91fa4ff
https://doi.org/10.1136/ejhpharm-2016-000875.522
https://doi.org/10.1136/ejhpharm-2016-000875.522